MedCap (Q3 initial take): Solid across the board - Redeye

Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimates. Continued outperformance by business areas Assistive Tech and MedTech fuelled this quarter’s top-line beat. While Specialty Pharma sales undershot our projection, its margin recovery continued during Q3 2025. Lastly, organic growth topped our estimate against decent references.

Länk till analysen i sin helhet: https://www.redeye.se/research/1132631/medcap-q3-initial-take-solid-across-the-board?utm_source=finwire&utm_medium=RSS